ERBB2 and neoplasm: Regarding the molecular tumor subtype, luminal A accounted for 33.7% of cases, luminal B HER2-negative for 27.6%, luminal B HER2-positive for 15.3%, HER2-enriched for 6.1%, and triple-negative for 17.3%.